Flipside Finance
AB

AbbVie Inc.

ABBVEquity
$206.60-2.23%
24h Volume: $0.01B

AI Summary

Updated 13h ago

AbbVie Inc

AbbVie Inc. (ABBV) is showing an interesting divergence. Price has pulled back — extension indicators are in the lower portion of their historical range — but buying pressure is holding up. Flow indicators remain above average despite the price weakness. For reference: Flow Score 51/100, Trend & Momentum Score 43/100.

48Neutral
Market position

Market Positioning

31Below avg
Extension
47Normal
Momentum
65Above avg
Flow
64Above avg
Volatility

What's Happening

Updated 6d ago

AbbVie scheduled Q1 2026 earnings call on March 31

AbbVie announced plans to host its Q1 2026 earnings conference call webcast at 8 a.m. Central time. This move signals confidence ahead of reporting—investors miss that early scheduling often precedes guidance reaffirms, with Q1 EPS guidance at $2.970–3.010 per company guidance.

The Bigger Picture

Updated 6d ago
Healthcare patent cliffs meet immunology growth surge
Humira erosion accelerates

Humira sales continue steep decline post-patent expiry, dragging overall EPS growth negative at -1.3% for 2025 trailing twelve months to $4.2 billion. Yet Skyrizi and Rinvoq ramp-up provided offset with Q4 revenue beats. Wall Street consensus sees EPS rebounding 13.57% to $13.98 in 2026 from $12.31.

Flow Score: 26/100Trend Score: 15/1003-Month Return: -9.4%

Upcoming Catalysts

Updated 6d ago
Apr 29Q1 2026 EarningsPassed

AbbVie reports Q1 results pre-open with consensus at $3.01 EPS on $14.72 billion revenue per analysts; watch guidance update versus FY2026 $14.370–14.570 EPS range from company.

Positive Catalyst
Earnings

Technical Analysis

Market Positioning

Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.

Extension
[avg: 31st]
31stpercentile
Low
Normal
High
31st percentile
Momentum
[avg: 47th]
47thpercentile
Low
Normal
High
47th percentile
Flow
[avg: 65th]
65thpercentile
Low
Normal
High
65th percentile
Volatility
[avg: 64th]
64thpercentile
Low
Normal
High
64th percentile

Key Levels

Demand: $200–$209 (1.1% below)
score: 7.32
Supply: $214–$246 (11.1% above)
score: 10.72
View full Key Levels section →

Looking at the full picture for AbbVie Inc. (ABBV): extension is slightly below average (31st percentile), momentum is neutral (47th percentile), flow is slightly above average (65th percentile), volatility is slightly above average (64th percentile). No dimension is showing an extreme reading right now. The indicators are not pointing to either a high-opportunity or high-risk setup — it is a wait-and-watch environment.

Conclusion

AbbVie Inc. (ABBV) sits in a relatively neutral position across all four dimensions — there is no extreme reading demanding attention right now. There is not a strong signal here in either direction. This is an asset to watch rather than act on right now. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.

Your portfolio. Your context. Smarter decisions.

Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.

AI + Portfolio

Personalized insights based on your actual holdings

Daily Briefing

Major market movements delivered to your inbox

Watchlists

Track the assets that matter most to you

Create your free account

No credit card required